CML may not be part of HUS

Am J Hematol. 1995 May;49(1):100-1. doi: 10.1002/ajh.2830490124.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Marrow Transplantation
  • Disease Progression
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • Hemolytic-Uremic Syndrome / chemically induced
  • Hemolytic-Uremic Syndrome / etiology*
  • Humans
  • Hydroxyurea / therapeutic use
  • Interferon Type I / adverse effects
  • Interferon-alpha / adverse effects*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / physiopathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Transplantation, Autologous

Substances

  • Interferon Type I
  • Interferon-alpha
  • Recombinant Proteins
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Hydroxyurea